#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians should understand that cannabis tax increases may not reduce patient use as expected, potentially limiting one policy tool for discouraging consumption in their patient populations. If higher taxes simply drive patients toward unregulated markets, clinicians lose visibility into product potency and contaminants, making it harder to counsel patients on actual exposure risks and dosing. This evidence suggests that clinical harm reduction strategies should not rely primarily on price mechanisms and may need to incorporate direct patient education and screening instead.
A recent analysis of cannabis consumption and tax data challenges the assumption that higher taxation effectively reduces marijuana use, finding instead that increased prices at state-licensed retailers may drive consumers toward illicit markets. This finding has important implications for state cannabis regulatory frameworks that rely on excise taxes as a primary policy tool to discourage consumption while generating public revenue. For clinicians counseling patients about cannabis use, understanding that taxation alone does not meaningfully reduce demand suggests that regulatory strategies must incorporate additional public health measures such as age restrictions, potency limits, and education campaigns to effectively influence consumption patterns. The shift toward illicit purchasing when legal products are heavily taxed also undermines quality control and product testing, potentially increasing patient exposure to contaminated or mislabeled products of unknown potency. Policymakers and clinicians should recognize that excessive taxation may be counterproductive to both public health and harm reduction goals. Clinicians should discuss with patients that cost-driven switches to unregulated markets may expose them to greater health risks than purchasing from regulated, tested sources.
“What we’re seeing in the data confirms what I observe in my practice: when legal cannabis becomes too expensive through taxation, patients don’t stop using it, they simply return to unregulated sources where I have no visibility into potency, contaminants, or safety, which actually increases my clinical risk and their health exposure.”
? While taxation is often proposed as a public health lever to reduce cannabis use, this research suggests that price increases at legal retailers may have limited deterrent effects and could paradoxically redirect consumers toward illicit markets with unregulated products of unknown potency and contaminant profiles. Healthcare providers should recognize that tax-based demand reduction strategies, though theoretically sound, operate within a complex market where legal and illegal suppliers coexist, and patients may have strong substitution behaviors that reduce the intended public health benefit. This finding underscores that screening and counseling interventions may be more reliable tools than policy-level price manipulation for addressing problematic cannabis use in clinical settings. When discussing cannabis use with patients, clinicians should acknowledge that cost barriers alone are unlikely to meaningfully alter consumption patterns and instead focus on motivational interviewing and assessment of use-related harms, particularly in populations where illicit sourcing remains common or where high-potency products pose emerging risks
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Read next
